KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial.

Babak B Navi, Mitchell S V Elkind, Cenai Zhang, David L Tirschwell, Richard A Kronmal, Jordan Elm, Joseph P Broderick, David J Gladstone, Morin Beyeler, Hooman Kamel, W T Longstreth

J Am Heart Assoc 14(9) e040543

PMID40265582
PMCIDPMC12184225
DOI10.1161/JAHA.124.040543
发表日期2025-04-23
入排依据:The record describes a secondary analysis of baseline data from the ARCADIA trial (a Phase III RCT for stroke prevention) examining biomarkers for atrial cardiopathy in relation to cancer history. While the parent trial is oncology-eligible in principle (randomized, phase 3, human), this specific report is not an efficacy analysis for an oncology outcome. It does not report survival, progression, recurrence, death, hazard, or time-to-event outcomes for cancer. It is a cross-sectional analysis of biomarkers as risk factors.
摘要

摘要

BACKGROUND: Approximately 50% of strokes in patients with cancer are classified as cryptogenic after standard evaluation. Atrial cardiopathy could explain some cancer-related cryptogenic strokes. However, the relationship between cancer and atrial cardiopathy is uncertain. METHODS AND RESULTS: We conducted a post hoc cross-sectional analysis of baseline data collected from participants enrolled in ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a clinical trial conducted from 2018 to 2023 at 185 sites. The analytical cohort presented herein included patients age ≥45 years with cryptogenic ischemic stroke within the past 180 days, of whom a subset had atrial cardiopathy and were randomized into the trial. Atrial fibrillation before enrollment was exclusionary. Linear regression models examined the associations between history of cancer and the atrial cardiopathy biomarkers analyzed in ARCADIA: serum NT-proBNP (N-terminal pro-B-type natriuretic peptide), P-wave terminal force in ECG lead V1, and left atrial diameter index on echocardiogram. Among 3745 patients with cryptogenic stroke, 506 (13.5%) had history of cancer. History of cancer was associated with higher median values of NT-proBNP (126 versus 103 pg/mL, P<0.001) and left atrial diameter index (1.9 versus 1.8 cm/m2, P<0.001) but similar median values of P-wave terminal force in ECG lead V1 (3000 versus 3025, P=0.08). After adjusting for demographics, tobacco use, and body mass index, no significant association remained between history of cancer and log-transformed NT-proBNP (standardized β$$ \beta $$, -0.06 [95% CI, -0.15 to 0.02]), P-wave terminal force in ECG lead V1 (standardized β$$ \beta $$, -0.02 [95% CI, -0.11 to 0.08]), or left atrial diameter index (standardized β$$ \beta $$, 0.06 [95% CI, -0.05 to 0.16]). CONCLUSIONS: In a multicenter, prospective, cryptogenic stroke cohort, history of cancer was not associated with selected biomarkers for atrial cardiopathy. REGISTRATION: URL: https://www.ClinicalTrials.gov; Unique Identifier: NCT03192215.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。